Abstract Details

Title Determining the Prevalence of Vitamin D Deficiency in a Neuromuscular Clinic

Topic Neurotoxicology

Presentation(s) P06 - (-)

Poster/Presentation
Number 212

Objective

Background BACKGROUND: Research has found that Vitamin D receptors are found throughout the body and play an important role in immune responses, inflammation, and neurodegeneration. Over one billion people worldwide are estimated to have either a Vitamin D deficiency or insufficiency. Insufficient or deficient levels of vitamin D have been associated with autoimmune conditions such as systemic lupus erythematous, depression, and multiple sclerosis. Our literature review found several case studies citing myopathy and treatment with Vitamin D supplementation; as well as one prospective study treating hypovitaminosis D in patients with myasthenia gravis. Currently, the prevalence of Vitamin D deficiency is unknown in patients with neuromuscular diseases.

Design/Methods DESIGN/METHODS: This was a retrospective study of a neuromuscular clinic from May 2010 through May 2012 looking for patients that had had a plasma 25(OH)D level checked and determine the prevalence of a Vitamin D deficiency in a neuromuscular patient population.

Results RESULTS: Of the 473 patients seen in clinic, 182 (112 females;70 males; mean age 54 years) patients were tested for plasma (OH)D level. 43% of those patients (87/182) were found to be deficient.

Conclusions CONCLUSIONS: Plasma 25(OH) levels were found to be deficient in 43% of patients in which the level was checked. The clinical significance of this is unclear and further investigation into the etiology for the deficiency and if certain neuromuscular diseases have a higher prevalence. Additional research is needed to determine the patient's response to corrective treatment. Based on our results we recommend checking 25(OH) levels for patients with neuromuscular disease to help optimize their treatment.

Authors/Disclosures
Julio Ventura, MD (Ascension St. Vincent'S Spine and Brain Neurology) PRESENTER	No disclosure on file
Sandeep S. Kahlon, MD (Kane Hall Barry Neurology)	No disclosure on file
Scott Vota, DO, FAAN	No disclosure on file
Hamid Sadeghian, MD	No disclosure on file
Gary R. Cutter, PhD (University of Alabama At Birmingham)	Dr. Cutter has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for onsulting or Advisory Boards: Alexion, Antisense Therapeutics/Percheron, Avotres, Biogen, Clene Nanomedicine, Clinical Trial Solutions LLC, Endra Life Sciences, Cognito Therapeutics, Genzyme, Genentech, Immunic, Klein-Buendel Incorporated, Kyverna Therapeutics, Inc. , Linical, Merck/Serono, Noema, Neurogenesis, Perception Neurosciences, Protalix Biotherapeutics, Regeneron, Revelstone Consulting, Roche, SAB Biotherapeutics, Sapience Therapeutics, Scott&Scott LLP, Tenmile.. Dr. Cutter has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Data and Safety Monitoring Boards: Applied Therapeutics, AI therapeutics, AMO Pharma, Argenx, Astra-Zeneca, Avexis Pharmaceuticals, Bristol Meyers Squibb, CSL Behring, Cynata Therapeutics, DiamedicaTherapeutics, Horizon Pharmaceuticals, Immunic, Inhibrix, Karuna Therapeutics, Kezar Life Sciences, Medtronic, Merck, Meiji Seika Pharma, Mitsubishi Tanabe Pharma Holdings, Prothena Biosciences, Novartis, Pipeline Therapeutics (Contineum), Regeneron, Sanofi-Aventis, Teva Pharmaceuticals, United BioSource LLC, University of Texas Southwestern.. Dr. Cutter has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JASN.

��ɫ��

��ɫ��